About Us
SLC6A1 SWITZERLAND is a non-profit association dedicated to improving the lives of people affected by the SLC6A1 neurodevelopmental disorder (SLC6A1-NDD). It was founded in March 2025 with the mission of becoming a point of reference in Switzerland for patients, families, and professionals in the medical and research fields.
​
SLC6A1-NDD is a rare condition, affecting approximately one in every 38,000 people. Based on prevalence rates, over 200 individuals in Switzerland are likely to be affected by this disorder, yet only a small fraction of this number has received a confirmed diagnosis. Our organisation is committed to identifying these undiagnosed individuals in order to ensure they receive the support they need.
​
We create opportunities for affected families to meet, support one another, and build a sense of community. We want no-one to feel alone in their fight against the disease.
​
We work to raise awareness among healthcare professionals so that patients receive timely diagnoses and appropriate treatment. We provide updates on the latest discoveries and are committed to making the most advanced therapies and medical practices used in other parts of the world available in Switzerland.
​
Advancing care for our loved ones is only possible through research. That’s why we dedicate our biggest efforts to supporting scientists who focus on SLC6A1. We support research projects in Switzerland and promote involvement in international initiatives by assisting researchers and specialized physicians.
​
Our strength lies in our global network. SLC6A1 SWITZERLAND is part of the SLC6A1 EUROPE Alliance, which closely collaborates with SLC6A1 CONNECT (USA). We are also watching with great interest the progress of research being conducted in Australia and around the rest of the world. We are one global team united by a single goal: to find targeted therapies for SLC6A1-related disorders.
SLC6A1 SWITZERLAND is a proud member of ProRaris, an alliance that brings together numerous organizations dedicated to rare diseases across Switzerland.
ProRaris serves as our collective voice at the political level, advocating for stronger involvement of patients and patient associations in shaping national health and pharmaceutical policies.
ProRaris is committed to improving access to timely diagnoses and appropriate care for people living with rare diseases — including the most advanced drug treatments and gene therapies.
​
Being part of this important alliance is essential for SLC6A1 SWITZERLAND, and we sincerely thank ProRaris for welcoming us as active members.
SLC6A1 SWITZERLAND is also a member of EURORDIS, the European Rare Disease Network. Membership enables us to stay informed about international initiatives, collaborate with like-minded organizations, and actively contribute to the advancement of research and care at the European level.